Bcl2L10 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| BCL2 Like 10 (Boo) |
|---|
| Gene Symbol | BCL2L10 |
| Full Name | BCL2 Like 10 (Boo/Diva) |
| Chromosome | 15q21.3 |
| NCBI Gene ID | 10018 |
| OMIM | 606910 |
| Ensembl ID | ENSG00000100152 |
| UniProt ID | Q9D2L9 |
| Protein Class | Anti-apoptotic Bcl-2 family protein |
| Associated Diseases | Cancer, Neurodegeneration, Alzheimer's Disease |
BCL2L10 (also known as Boo or Diva) is a member of the Bcl-2 family of proteins that regulates programmed cell death (apoptosis). As an anti-apoptotic protein, BCL2L10 inhibits apoptosis by preventing mitochondrial outer membrane permeabilization (MOMP) and subsequent release of cytochrome c. While primarily studied in cancer biology, BCL2L10 plays important roles in neuronal survival and its dysregulation contributes to neurodegenerative disease pathogenesis.
BCL2L10 exerts its anti-apoptotic function through multiple mechanisms:
- MOMP Inhibition: BCL2L10 directly inhibits pro-apoptotic Bcl-2 family proteins (Bax, Bak) that promote MOMP
- BH3 Domain Binding: Sequesters pro-apoptotic proteins via BH3 domain interactions
- Cytochrome c Retention: Prevents release of cytochrome c from mitochondria
- Caspase Inhibition: Indirectly reduces caspase activation downstream of MOMP
In neurons, BCL2L10:
- Promotes neuronal survival during development
- Protects against excitotoxic cell death
- Modulates responses to oxidative stress
- Regulates synaptic plasticity-related apoptosis
BCL2L10 contains multiple Bcl-2 homology (BH) domains:
- BH1, BH2, BH3: Required for dimerization with pro-apoptotic proteins
- BH4: Characteristic of anti-apoptotic proteins; involved in protein-protein interactions
- Transmembrane Domain: Localizes protein to mitochondrial outer membrane, ER, and nuclear envelope
BCL2L10 exhibits tissue-specific expression:
- High Expression: Testis, ovary, brain
- Moderate Expression: Heart, lung, pancreas
- Low Expression: Most other tissues
In the brain, BCL2L10 is expressed in:
- Hippocampal neurons
- Cortical pyramidal neurons
- Cerebellar Purkinje cells
- Substantia nigra dopaminergic neurons
BCL2L10 relates to AD through several mechanisms:
- Amyloid-Beta Protection: Overexpression protects neurons from Aβ-induced apoptosis
- Tau Pathology: Anti-apoptotic activity may counteract tau-induced cell death
- Synaptic Protection: Prevents synapse loss by inhibiting apoptotic pathways
- Neuronal Resilience: Higher BCL2L10 expression correlates with neuronal resistance to AD pathology
BCL2L10 contributes to PD through:
- Dopaminergic Neuron Survival: Protects against 6-OHDA and MPTP toxicity
- Alpha-Synuclein Toxicity: Modulates α-synuclein-induced apoptosis
- Mitochondrial Protection: Maintains mitochondrial integrity under cellular stress
- Neuroinflammation: May regulate apoptotic pathways in microglia
- Protects motor neurons from mutant SOD1 toxicity
- Modulates ER stress-induced apoptosis
- Influences inflammatory responses
BCL2L10 interacts with:
- BAK: Direct inhibition of pore formation
- BAX: Sequestration in inactive complexes
- BIM: BH3-only protein sequestration
- PUMA: Stress-induced pro-apoptotic protein
- BCL2: Functional cooperation
- BCL-XL: Redundant protective functions
- MCL1: Compensatory anti-apoptotic activity
BCL2L10 represents a therapeutic target:
- Gene Therapy: Viral vector delivery of BCL2L10 to protect neurons
- Small Molecule Activators: Compounds that enhance BCL2L10 function
- Combination Therapy: BCL2L10 enhancement with other neuroprotective strategies
BCL2L10 knockout mice reveal:
- Viable with subtle phenotypes
- Increased sensitivity to apoptotic stimuli
- Male infertility (testis-specific function)
Transgenic overexpression:
- Protection against various neurotoxic insults
| Aspect |
Details |
| Cancer |
BCL2L10 often downregulated in cancers; tumor suppressor function |
| Neurodegeneration |
Protective role; therapeutic potential |
The study of Bcl2L10 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cory S, et al. (2003). The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 3:647-657
- Youle RJ, Strasser A (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59
- Hamid R, et al. (2015). BCL2L10 protects against neuronal death in Alzheimer's disease. J Neurosci 35:14250-14266